Good morning :)
Place Order
Add to Watchlist

Advanced Enzyme Technologies Ltd

ADVENZYMES

Advanced Enzyme Technologies Ltd

ADVENZYMES
MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹4,098 cr, stock is ranked 830
Moderate RiskStock is 2.88x as volatile as Nifty
366.351.23% (-4.55)
366.351.23% (-4.55)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹4,098 cr, stock is ranked 830
Moderate RiskStock is 2.88x as volatile as Nifty

How to use scorecard? Learn more

MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹4,098 cr, stock is ranked 830
Moderate RiskStock is 2.88x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
29.902.991.39%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
29.463.341.38%

Forecast & Ratings

Detailed Forecast 
0%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Advanced Enzyme Technologies is engaged in the research and development, manufacturing and marketing of over 400 products developed from over 60 indigenous enzymes.

Investor Presentation

View older 

Nov 9, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.24%, vs industry avg of 6.11%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.76% to 0.78%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 3.72%, vs industry avg of -1.53%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue295.05331.57392.41424.63449.63510.69535.80566.10660.53659.87
Raw Materialssubtract69.6670.1480.3365.9590.83100.21130.32127.53155.47431.79
Power & Fuel Costsubtract10.1712.8718.1019.2919.3721.4529.9538.1040.92
Employee Costsubtract44.5050.7068.6080.2380.1987.11103.96114.80128.37
Selling & Administrative Expensessubtract23.5025.6138.4140.0437.5837.7251.8056.2260.11
Operating & Other expensessubtract12.4718.0020.6430.8412.6522.7810.7750.5648.48
Depreciation/Amortizationsubtract8.7212.7618.3021.1225.7828.7234.9835.0335.2435.39
Interest & Other Itemssubtract7.864.439.065.204.082.572.963.484.123.33
Taxes & Other Itemssubtract42.3445.5148.9150.9049.8764.2151.4834.7554.5252.30
EPS1.392.798.079.9511.5813.0610.709.4511.9212.26
DPS0.200.080.500.600.600.901.001.005.105.10
Payout ratio0.140.030.060.060.050.070.090.110.430.42

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 20PDF
Feb 5PDF
Nov 2PDF
Nov 2PDF
FY 2023

Annual report

PDF

Investor Presentation

May 13PDF
Feb 11PDF
Nov 11PDF
Aug 6PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 12PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 9PDF
 

Peers & Comparison

Comparing 3 stocks from 
MaterialsSpecialty Chemicals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Advanced Enzyme Technologies Ltd30.752.991.39%
Gujarat Fluorochemicals Ltd96.227.050.08%
Vinati Organics Ltd59.097.750.38%
Akzo Nobel India Ltd38.8512.461.79%

Price Comparison

Compare ADVENZYMES with any stock or ETF
Compare ADVENZYMES with any stock or ETF
ADVENZYMES
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding42.95%5.57%2.46%12.63%36.41%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep21.90%22.27%22.54%23.01%12.03%12.63%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Advanced Enzyme Technologies Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Small Cap Fund - Growth - Direct Plan

Growth
3.3101%0.40%0.04%58/92 (-17)
UTI AMC LTD # UTI MF-UTI MNC FUND DIRECT PLAN GROWTH PLAN GROWTH

Growth
1.1544%1.56%0.26%27/51 (+4)
ICICI Prudential ESG Exclusionary Strategy Fund - Growth - Direct Plan

Growth
1.0066%2.65%-0.04%11/51 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ADVENZYMES has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.39%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹13.91 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 18, 2024

Final
Final | Div/Share: ₹1.10

Dividend/Share

1.10

Ex DateEx Date

Jul 18, 2024

Cash Dividend

Ex DateEx DateMay 17, 2024

Interim
Interim | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

May 17, 2024

Cash Dividend

Ex DateEx DateAug 4, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Aug 4, 2023

Cash Dividend

Ex DateEx DateMay 19, 2023

Interim
Interim | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

May 19, 2023

Cash Dividend

Ex DateEx DateAug 11, 2022

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Aug 11, 2022

News & Opinions
Spotlight
Advanced Enzyme Tech drops after PAT slides 5% YoY in Q2 FY25

The revenue de-grew by 3% in Americas, 27% in Europe, 9% in Asia (ex-India) while it grew by 8% in rest of the world. On the segmental front, the revenue from human nutrition segment declined by 2% YoY to Rs 99.2 crore while animal nutrition income grew by 6% YoY to Rs 18.1 crore in second quarter of FY25. The bio-processing segment revenue slipped 33% to Rs 16.8 crore while specialized manufacturing segment rose 9% to Rs 12 crore in September 2024 quarter over September 2023 quarter. The domestic sales constituted about 48% of revenue from operations during Q2 FY25 as compared to 52% during Q2 FY24. International sales were 52% of revenue from operations during Q2 FY25 as compared to 48% during same quarter last year. EBITDA de-grew by 17% YoY to Rs 42.4 crore in the second quarter. EBITDA margin was 29% and PAT margin stood at 23% during the quarter. Profit before tax was at Rs 42.21 crore during Q2 of FY25, down 11.93% YoY. On outlook front, the company stated, 'Advanced Enzymes is constantly working towards improving and strengthening its business model, and will continue to focus on all three divisions - Human Nutrition, Animal Nutrition and Bio-Processing including developing, adding and launching more products in the target market of probiotics. The company is confident that its existing capacities and capital investments would serve well to expand its enzymes and probiotics business.' Advanced Enzyme Technologies is a research driven company with global leadership in the manufacturing of enzymes and probiotics. The company provides eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. Its aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions. Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Advanced Enzyme Technologies consolidated net profit declines 4.59% in the September 2024 quarter

Net profit of Advanced Enzyme Technologies declined 4.59% to Rs 32.83 crore in the quarter ended September 2024 as against Rs 34.41 crore during the previous quarter ended September 2023. Sales declined 7.44% to Rs 146.10 crore in the quarter ended September 2024 as against Rs 157.84 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales146.10157.84 -7 OPM %29.0332.51 - PBDT51.1056.65 -10 PBT42.2147.93 -12 NP32.8334.41 -5 Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Advanced Enzyme Techs. announces board meeting date

Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Advanced Enzyme Techs. to table results

Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Advanced Enzyme Technologies consolidated net profit rises 18.54% in the June 2024 quarter

Net profit of Advanced Enzyme Technologies rose 18.54% to Rs 34.15 crore in the quarter ended June 2024 as against Rs 28.81 crore during the previous quarter ended June 2023. Sales rose 4.92% to Rs 154.52 crore in the quarter ended June 2024 as against Rs 147.28 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales154.52147.28 5 OPM %33.1229.89 - PBDT57.2950.04 14 PBT48.6741.41 18 NP34.1528.81 19 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Advanced Enzyme Techs. announces board meeting date

Advanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Stock alert: Indus Towers, Gland Pharma, Advanced Enzyme, DMart, Sapphire Foods

5 months agoBusiness Standard

Motilal Oswal Buys Shares Of Advanced Enzyme Technologies For Rs 425.5 Crore

5 months agoBloomberg Quint

Advanced Enzyme jumps 4% as ICICI Mutual Fund acquires stake

1 year agoMoneycontrol

Advanced Enzyme Technologies Ltd Spurts 2.63%

1 year agoBusiness Standard